Subdermal Contraceptive Implants Market Size & Growth Forecast 2027–2036, By Segments (Product, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Subdermal Contraceptive Implants Market size was worth USD 1.3 billion in 2026 and is poised to grow at a 7.22% CAGR between 2027 and 2036, crossing USD 2.61 billion by 2036. The industry revenue for 2027 is assessed at USD 1.38 billion.
Get more details on this report
Request Free Sample ReportSubdermal Contraceptive Implants Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 62.96% share due to established contraceptive care pathways, broad access to trained providers, strong awareness of long-acting reversible contraception, and routine integration into family planning services.
- Asia Pacific is fastest-growing at 8.7% CAGR, driven by expanding family planning programs, improving access to reproductive healthcare, increasing provider availability, and growing adoption of implant-based contraception.
Segment Momentum
- Etonogestrel Implant held a 62.79% share in 2026, supported by broad clinical adoption, established treatment pathways, and provider familiarity that reinforce procurement and routine contraceptive use.
- Gynecology clinics are growing fastest because their specialized reproductive health services provide focused contraceptive counseling and streamlined implant procedures that align well with routine women's healthcare visits.
Market Expansion Drivers
- Rising unintended pregnancies increasing demand for long-acting reversible contraceptive solutions.
- Government family planning initiatives expanding access to subdermal contraceptive implant programs.
- Advancements in biocompatible implant materials improving patient comfort and procedural acceptance.
Leading Market Participants
- Top companies in the subdermal contraceptive implants market include Merck & Co., Inc. (United States), Bayer AG (Germany), Shanghai Dahua Pharmaceutical Co., Ltd. (China), Gerresheimer AG (Germany), SCHOTT AG (Germany), Pfizer Inc. (United States), Becton, Dickinson and Company (United States), Eli Lilly and Company (United States), Novartis AG (Switzerland), Baxter International Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.3 billion
- 2027 Estimated Market Size: USD 1.38 billion.
- Projected Market Size: USD 2.61 billion by 2036
- Growth Forecast: 7.22% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Etonogestrel Implant (Product) | Hospital (Distribution Channel)
- Emerging Opportunity Segment: Levonorgestrel Implant (Product) | Gynecology Clinics (Distribution Channel)
Market Growth Drivers and Industry Trends
Rising unintended pregnancies increasing demand for long-acting reversible contraceptive solutions
High levels of unintended pregnancy will drive the subdermal contraceptive implants market by increasing interest in contraceptive methods that provide sustained pregnancy prevention without requiring frequent user action. Subdermal implants offer long-duration contraception through a single placement procedure, making them suitable for individuals seeking an effective option that does not depend on daily adherence. Greater awareness of reproductive health and the availability of multiple contraceptive choices are encouraging women to consider long-acting reversible methods according to their individual needs and preferences. The convenience associated with prolonged protection can also be particularly valuable for individuals who experience difficulties maintaining consistent use of short-acting contraceptive methods.
Government family planning initiatives expanding access to subdermal contraceptive implant programs
Public-sector family planning programs will expand the subdermal contraceptive implants market by improving awareness, availability, counseling, and access to long-acting contraceptive options in underserved populations. Government-supported reproductive health initiatives can incorporate implants into broader contraceptive service delivery through public healthcare facilities, community-based programs, and trained healthcare providers. Such efforts help address barriers related to affordability, geographic access, and limited knowledge of available methods while enabling individuals to make informed contraceptive decisions. Increased integration of implant services into routine family planning programs can also strengthen provider familiarity with insertion and removal procedures and support wider availability across healthcare settings.
Advancements in biocompatible implant materials improving patient comfort and procedural acceptance
Developments in biocompatible materials are contributing to the subdermal contraceptive implants market by supporting implant designs that are better tolerated within the body and more acceptable to users. Improvements in material properties can help reduce local irritation and support compatibility with surrounding tissue while maintaining the controlled release characteristics required for long-acting contraception. Refinements in implant size, flexibility, surface characteristics, and delivery design can also make insertion and removal procedures more manageable for healthcare providers and patients. Greater attention to comfort and user experience is important for contraceptive adoption because concerns about implantation procedures or device-related discomfort can influence willingness to select long-acting reversible methods.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising unintended pregnancies increasing demand for long-acting reversible contraceptive solutions | 2.00% | High | Asia Pacific, Africa | High | Near Term |
| Government family planning initiatives expanding access to subdermal contraceptive implant programs | 1.70% | High | Asia Pacific, Latin America | High | Mid Term |
| Advancements in biocompatible implant materials improving patient comfort and procedural acceptance | 1.40% | Moderate | North America, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
Holding the largest share of the subdermal contraceptive implants market, North America accounted for 62.96% in 2026. The region benefits from established reproductive healthcare systems, broad awareness of long-acting contraceptive options, and greater access to family-planning services. Preference for convenient and durable contraception is supporting demand, while healthcare professionals’ familiarity with implant-based methods facilitates their integration into reproductive health programs. Continued emphasis on informed contraceptive choice and accessible reproductive care further supports regional adoption.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region as healthcare access expands and awareness of long-acting contraceptive methods increases. Improvements in reproductive health services and broader availability of modern family-planning options are creating favorable conditions for implant adoption. Growing attention to effective, convenient contraception, combined with strengthening healthcare infrastructure, is supporting wider acceptance across diverse populations.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants/Startups i Scale Low Medium High | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Preventive Women's HealthcareGermany integrates subdermal contraceptive implants into comprehensive reproductive healthcare services emphasizing long-term contraceptive effectiveness. Medical professionals focus on informed patient choice, standardized clinical procedures, and sustained access to modern contraceptive technologies.
France 🇫🇷
Reproductive Health AccessibilityFrance promotes subdermal contraceptive implants as part of accessible reproductive healthcare programs focused on long-term contraception. Healthcare systems encourage informed decision-making while supporting consistent availability through established clinical care pathways.
Italy 🇮🇹
Clinical Contraceptive AdoptionItaly's subdermal contraceptive implants market reflects increasing clinical acceptance of long-acting contraceptive methods within women's healthcare services. Medical providers prioritize safe implantation procedures, patient follow-up, and individualized contraceptive planning to improve reproductive health outcomes.
Japan 🇯🇵
Personalized Contraceptive CareJapan's subdermal contraceptive implants market develops gradually through greater awareness of individualized family planning solutions. Healthcare providers emphasize patient education and careful clinical evaluation to support appropriate adoption of long-acting contraceptive methods.
South Korea 🇰🇷
Modern Family PlanningSouth Korea supports broader adoption of subdermal contraceptive implants through expanding reproductive healthcare services and patient education. The market emphasizes minimally invasive procedures and convenient long-term contraception suited to evolving healthcare preferences.
United States 🇺🇸
Long-Acting Contraceptive AccessThe U.S. subdermal contraceptive implants market is supported by increasing preference for long-acting reversible contraception across diverse healthcare settings. Healthcare providers prioritize patient counseling, expanded access, and effective reproductive health management through implant-based contraceptive options.
Segment Leadership and Growth Trends
Subdermal Contraceptive Implants Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Etonogestrel Implant (Largest Segment) vs Levonorgestrel Implant (Fastest-Growing Segment)
The etonogestrel implant segment dominated the subdermal contraceptive implants market in 2026, accounting for a 62.79% share. Its established use as a long-acting reversible contraceptive is supported by its high contraceptive effectiveness, convenient administration, and extended duration of protection, which can improve adherence compared with methods requiring frequent user intervention. Increasing preference for reliable, low-maintenance contraception and broader awareness of long-acting methods continue to support demand for etonogestrel-based implants.
Levonorgestrel implants are expected to register the fastest growth as contraceptive programs and healthcare providers seek additional long-acting options that can address diverse patient preferences. Their suitability for reversible contraception and their role in expanding the range of implant-based choices can support greater adoption. Continued emphasis on accessible family-planning services and patient-centered contraceptive care is also expected to strengthen interest in levonorgestrel implants.
Distribution Channel Segment Analysis: Hospital (Largest Segment) vs Gynecology Clinics (Fastest-Growing Segment)
In the subdermal contraceptive implants market, hospitals held the largest share in 2026, representing 57.09% of the market. Hospitals provide established clinical infrastructure, trained healthcare professionals, and access to a broad range of reproductive health services, making them important settings for implant insertion, counseling, and follow-up care. Their ability to manage contraceptive procedures within integrated healthcare environments continues to support their leading distribution role.
Gynecology clinics are anticipated to grow at the fastest rate as patients increasingly seek specialized reproductive healthcare in more focused and accessible clinical settings. These facilities can provide dedicated counseling, implant placement, and follow-up services, enabling a streamlined experience for individuals choosing long-acting contraception. Greater emphasis on specialized women's healthcare and convenient outpatient services is expected to encourage the expansion of this channel.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Etonogestrel Implant, Levonorgestrel Implant | Etonogestrel Implant | Levonorgestrel Implant |
| Distribution Channel | Hospital, Gynecology Clinics, Community Health Care Centers, Others | Hospital | Gynecology Clinics |
Competitive Landscape and Market Positioning
Leading companies in the subdermal contraceptive implants market:
1. Merck & Co. Inc. (United States)
2. Bayer AG (Germany)
3. Shanghai Dahua Pharmaceutical Co. Ltd. (China)
4. Gerresheimer AG (Germany)
5. SCHOTT AG (Germany)
6. Pfizer Inc. (United States)
7. Becton Dickinson and Company (United States)
8. Eli Lilly and Company (United States)
9. Novartis AG (Switzerland)
10. Baxter International Inc. (United States)
The subdermal contraceptive implants market is experiencing increased focus on long-acting and user-convenient birth control solutions. Development efforts are centered on improving implant efficacy, reducing side effects, and extending duration of effectiveness. Rising awareness regarding reproductive health options and the growing preference for minimally invasive contraceptive methods continue to support market expansion.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Merck & Co. Inc. (United States) | |||||||
| Bayer AG (Germany) | |||||||
| Shanghai Dahua Pharmaceutical Co. Ltd. (China) | |||||||
| Gerresheimer AG (Germany) | |||||||
| SCHOTT AG (Germany) | |||||||
| Pfizer Inc. (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Eli Lilly and Company (United States) | |||||||
| Novartis AG (Switzerland) | |||||||
| Baxter International Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Mass General Brigham & MIT | Mar-25 | Researchers developed a novel long-acting contraceptive delivery platform using Self-assembling Long-acting Injectable Microcrystals (SLIM) technology. This system enables administration through fine-gauge needles, effectively eliminating the requirement for traditional surgical insertion and removal procedures, thereby significantly improving patient comfort and lowering barriers to accessing long-term reproductive healthcare. |
| FDA | Feb-25 | The FDA approved MIUDELLA, the first hormone-free copper intrauterine system to reach the U.S. market in over four decades. This regulatory approval expands the landscape of available long-acting reversible contraception (LARC) and signals a shift toward diversifying non-hormonal options, which may influence future approval pathways for similarly innovative, non-surgical contraceptive implant technologies. |
| Shanghai Dahua Pharmaceutical | 2025 | Shanghai Dahua Pharmaceutical significantly expanded its manufacturing capacity for contraceptive implants to address rising global demand, particularly in emerging markets. This scale-up aims to support international procurement programs and enhance the global supply chain for cost-effective, high-quality contraceptive solutions, reinforcing the company's role as a major volume supplier of LARC devices. |
| Gerresheimer AG | 2025 | Gerresheimer AG introduced advanced specialized packaging technologies designed to improve the stability and shelf-life of subdermal contraceptive implants. By leveraging sophisticated material science and precise containment solutions, the company addresses critical stability requirements for hormone-releasing devices, ensuring product integrity during transport and storage in diverse global climates. |
| Organon | Feb-24 | Organon launched the "Her Plan is Her Power" global initiative, a strategic market access program combining community engagement, listening tours, and grant funding in high-need U.S. communities. This shift emphasizes comprehensive care models that link product availability with educational support, addressing social barriers to contraception adoption and improving long-term patient adherence to LARC methods. |
| Bayer AG | Feb-24 | Bayer AG entered into a strategic collaboration with Daré Bioscience to co-develop and expand access to innovative, hormone-free monthly contraceptive options. This partnership reflects a strategic broadening of Bayer’s reproductive health portfolio, integrating differentiated technologies to provide women with a wider spectrum of choice beyond traditional single-rod hormonal implants. |
| Becton Dickinson (BD) | 2024 | BD launched improved, ergonomically optimized implant insertion devices specifically designed for outpatient clinical settings. By streamlining the procedural interface for healthcare providers, these tools aim to reduce insertion-related errors and complications, improving the clinical experience and efficiency of subdermal implant procedures in primary care and family-planning environments. |
| Merck & Co., Inc. | 2023 | Merck & Co. expanded its long-acting contraceptive implant distribution programs, focusing on increasing the availability of LARC methods in underserved and public-sector markets. This effort represents a significant commitment to reducing regional disparities in reproductive healthcare access by scaling the logistics and distribution networks required to support the adoption of long-term pregnancy prevention solutions. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Subdermal Contraceptive Implants Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Patient Age Group | Adolescents and Young Adults, Adults, Women of Advanced Reproductive Age |
| Implant Duration | Up to 3 Years, 3–4 Years, More Than 4 Years |
| Access Program Type | Commercially Purchased Implants, Government-Supported Programs, NGO and Donor-Supported Programs |
Subdermal Contraceptive Implants Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Family Planning Program Opportunity Assessment |
|
| Long-Acting Contraception Adoption Analysis |
|
| Public Health Procurement Landscape |
|
Need a different cut of the data?
Request Custom ResearchHow large is the subdermal contraceptive implants market?
What is the anticipated CAGR of the subdermal contraceptive implants industry?
How are family planning initiatives supporting growth in the subdermal contraceptive implants market?
Why are improvements in implant materials influencing adoption in the subdermal contraceptive implants market?
Why is the Etonogestrel Implant the leading product segment in the subdermal contraceptive implants market?
Why are gynecology clinics the fastest-growing distribution channel in the subdermal contraceptive implants market?
Why is North America leading the subdermal contraceptive implants market?
What is driving the fastest growth in Asia Pacific contraceptive implants market?
Who holds a significant market share in the subdermal contraceptive implants landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization